Peter J. Courossi

Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA.

Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA.

Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY.

Mascoma Corp. develops technology for abundant biomass conversion. The firm operates through its bioprocessing technology platform, develops bioengineered yeasts and other microorganisms. It also designs and manufactures equipment that processes cellulosic biomass for further biological or chemical conversion. The company was founded by Lee R. Lynd, Charles E. Wyman and Robert J. Johnsen in 2005 and is headquartered in Waltham, MA.

Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Beecken Petty O'Keefe & Co LP (BPOC) is a private equity firm founded in 1996 by Dave Beecken, Bill Petty, and Ken O’Keefe. The firm is headquartered Chicago, Illinois.

The Chicago Symphony Orchestra Association operates music bands and orchestras. The non-profit company is based in Chicago, IL.

Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ.

Baxter BioScience Corp. provides biopharmaceutical and vaccines services. It offers a portfolio of therapeutic proteins derived from either human plasma or recombinant technology. The company is headquartered in Beltsville, MD.

Illinois Biotechnology Industry Organization, also known as ibio, is a state trade association representing the life sciences industry in Illinois. The non-profit company is based in Chicago, IL. The organization's mission is to promote, connect, and engage the life sciences community to drive discovery, transform lives through groundbreaking research, and grow the economy. The company's membership ranges from corporations to startup companies in the biopharma, medical device, and nutrition industries. The Illinois life sciences industry is recognized as a national leader, and ibio's members are committed to expanding the boundaries of science by discovering, developing, and delivering innovative and needed therapeutics and products to transform patients' lives.

KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom.

Baxter Ventures (Baxter Ventures) is a venture capital firm subsidiary of Baxter International, Inc. founded in 2011. The firm is headquartered in Deerfield, Illinois.

Zytoprotec GmbH develops and manufactures drugs for peritoneal dialysis. It specializes in the research and development of its pipeline, which encompasses PD-protec, a patented-protected solution and ICO-protec, a cytoprotective PD solution to address the market for non-glucose based PD solutions. The firm focus areas encompass portfolio management, therapeutic approach, patent management and research services. The company was founded by Karl Altenhuber, Christoph Aufricht and Christian Hoenig in 2007 and is headquartered in Vienna, Austria.

Affinivax, Inc. operates as a biotechnology company which develops novel conjugation technology. The company is headquartered in North Cambridge, MA.

The Austrian Academy of Sciences provides humanities and social science research services. The private company is based in Vienna, Austria.

Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts.

Cerevel Therapeutics LLC operates as a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system. The company was founded in 2018 and is headquartered in Boston, MA.

ProKidney LLC develops therapies for kidney disease. The company was founded by Pablo Legorreta and is headquartered in Winston-Salem, NC.

Tacitus Therapeutics, Inc. operates as a clinical-stage biotechnology firm. The company was founded by Ronald Hoffman and Camelia Iancu-Rubin and is headquartered in Albany, NY.

Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018.

Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles.